POST SUMMARY: The number of over-65s on the planet is projected almost to triple between 2010 and 2050 to 1.5bn, according to the UN. This, in turn, will spur a surge in age-related diseases such as cancer. The World Health Organization predicts the number of cases will increase 70 per cent in the next 20 years. Global spending on cancer drugs has more than doubled in the past decade to $91bn in 2013, according to the IMS Institute for Healthcare Informatics. However, can the US healthcare system really afford $100,000 drugs?
Source: Financial Times “Counting the cost of cancer” Continue reading »
POST SUMMARY: According to an editorial in today’s Times “pharma companies are taking advantage of a mix of laws that force insurers to include essentially all expensive drugs in their policies, and a philosophy that demands that every new health care product be available to everyone, no matter how little it helps or how much it costs.”
Continue reading »
POST SUMMARY: Researchers find that nearly 70 percent of Americans are on at least one prescription drug, and more than half receive at least two prescriptions, but why medications are prescribed should not be determined by pharma pressure on medical/scientific guidelines. Continue reading »
POST SUMMARY: The largest manager of U.S. prescription-drug benefits is taking sides in a fight between new hepatitis C treatments that cost close to $100,000 per patient. Continue reading »
POST SUMMARY: There are a lot of new medications getting positive PR in the war on cancer, but when and how will the industry get patients involved and ask what’s important to them? Continue reading »
POST SUMMARY: While mobile is on fire as a way to access the Internet and to check email and message friends suggesting that text messaging can increase compliance may not be the answer for your product. Continue reading »
POST SUMMARY: If you want to understand why so many people are turning away from traditional journalists as news sources look no further than an article in VOX entitled “This drug costs $84,000, And there’s nothing the US health-care system can do to stop it.” It’s time to look beyond the cost and instead look at the value of these medications.
Continue reading »
POST SUMMARY: The media has done a bad job in reporting on the high costs of drug prices, but a recent article in HBR finally sheds some common sense on drug pricing Continue reading »
POST SUMMARY: As long as the majority of patients choose not to be compliant and don’t follow doctor’s orders insurers should not compensate physicians on patient outcomes. Continue reading »
POST SUMMARY: Spending on cancer medicines represents less than 1 percent of all health care spending for all diseases —$25.9 billion out of $2,800 billion. Cancer medicines represent 20 percent of total spending on cancer care. But don’t let facts get in the way of a good media story. Continue reading »
POST SUMMARY: The current model of the way cancer drugs are prices is unsustaianable and innovation is needed both to develop new drugs and price them in a way that ensures the drug is priced on “the value” it brings to patients. Continue reading »